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Abstract
Therapy-related acute leukemia (t-AML), is a severe complication of cytotoxic therapy used for primary cancer treatment.
The outcome of these patients is poor, compared to people who develop de novo acute leukemia (p-AML). Cytogenetic
abnormalities in t-AML are similar to those found in p-AML but present more frequent unfavorable karyotypes depending
on the inducting agent. Losses of chromosome 5 or 7 are observed after alkylating agents while balanced translocations are
found after topoisomerase II inhibitors. This study compared t-AML to p-AML using high resolution array CGH in order to
find copy number abnormalities (CNA) at a higher resolution than conventional cytogenetics. More CNAs were observed in
30 t-AML than in 36 p-AML: 104 CNAs were observed with 63 losses and 41 gains (mean number 3.46 per case) in t-AML,
while in p-AML, 69 CNAs were observed with 32 losses and 37 gains (mean number of 1.9 per case). In primary leukemia
with a previously ‘‘normal’’ karyotype, 18% exhibited a previously undetected CNA, whereas in the (few) t-AML with a
normal karyotype, the rate was 50%. Several minimal critical regions (MCRs) were found in t-AML and p-AML. No common
MCRs were found in the two groups. In t-AML a 40kb deleted MCR pointed to RUNX1 on 21q22, a gene coding for a
transcription factor implicated in frequent rearrangements in leukemia and in familial thrombocytopenia. In de novo AML, a
1Mb MCR harboring ERG and ETS2 was observed from patients with complex aCGH profiles. High resolution cytogenomics
obtained by aCGH and similar techniques already published allowed us to characterize numerous non random chromosome
abnormalities. This work supports the hypothesis that they can be classified into several categories: abnormalities common
to all AML; those more frequently found in t-AML and those specifically found in p-AML.
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Introduction
Therapy-related myeloblastic leukemia, including therapy-
related myelodysplasia, (t-AML), constitutes approximately 10%
of AML and has several characteristic features [1,2]. As the
incidence of cancers increases, so does that of t-AML. Nowadays,
thanks to treatment intensification, the cure rate of primary
neoplasia has increased but these very treatments are also
implicated in severe therapy-related hematological consequences.
Factors associated with the development of t-AML include prior
cytotoxic therapy. Two different types of t-AML are to be
distinguished. The first one is due to prior therapy with alkylating
agents (AA) or radiotherapy [1,2,3,4]. It occurs generally after a
latency period of 5 to 7 years. This kind of t-AML is often preceded
by a preleukemic period of myelodysplasia (t-MDS). Approximately
90% of the patients with AA-related t-AML exhibit clonal
chromosomal aberrations including monosomy or deletions on
chromosome 5 and/or 7, or complex aberrations involving
chromosome 3, 12, 17 and 21. Drugs that target topoisomerase II
(ATII), such as etoposide and anthracyclines may induce the second
type of t-AML [1,2,3,4]. It occurs in a median of 2 years and is not
preceded by MDS. Cytogenetic analysis shows a high frequency of
rearrangements of chromosome band 11q23 but also recurrent
balanced rearrangements t(8;21), t(15;17) and inv(16) [1,2].
The prognosis is poor in t-AML, excepted in case of t(8;21), t(15;17)
and inv(16) which follow the same course as p-AML and the karyotype
is more frequently modified with at least 2 abnormalities or more.
p-AML are also heterogeneous entities, classified according to
bone marrow cell morphology and karyotype with the recent
addition of several gene mutations. AML was among the first
diseases to be treated and monitored according to somatic
acquired chromosomal abnormalities, including the first successful
targeted treatment against a pathological gene product in AML3.
As t-AML appear to have a particular leukemogenesis pathway
[3,4], the aims of this work were:
1) to analyze t-AML using high resolution array CGH in order to
find genome region or even gene-specific copy number abnormal-
ities (CNA) at a higher resolution than conventional cytogenetics; 2)
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16623Table 1. Clinical, biological features and karyotype of t-AML patients.
Pts1 Age
2/ Primary
3 -P C T t 4 FAB5 Karyotype at diagnosis of t-AML FISH6 p-AML AML Allog.9 Survival.
Sex Cancer
3 - Type
7 Tt
8 12 month
t-1 71/F Ovarian Tax/SP/PSC833/Iressa RAEB 57,XXX,+1,+4,del(5)(q15;q33)62,27,
+8,+9,
MLL WT A no no no
C. +13,+14,217,+18,+19,220,+22,+mar [4]
t-2 67/F VLSL Fluda/Chlorambucil AML-M5 44, XX, 5q-, 27, 212, 214, 218,
+ der(12?)
MLL WT A no no dead at
+mar [20] diagnosis
t-3 44/F Breast C Alk/AT II AML-M0 46,XX,der(1)t(1;17)(p36;?),der(7) MLL ND U yes yes yes
Lipo- t(7;?)(p15;?),der(10)(7;10;17)(?;p11;
sarcoma q?21),der(17)(q11?),ins(17?) [11]
t-4 45/F Astrocy-, RT/BCNU/Alk/ AML-M0 45,XX,dup(2)(q22;q34),-3p21, MLL WT U yes no no
toma AT II, Autograft t(5;13)(p15;q14),t(6;8)(p21;q24),+i(7q)
+ skin ,der(7)t(7;15)(q10;q10),der(12)
T NHL t(12;17)(p13;q11),215,217 [18]
t-5 72/M Esophag. 5FU/SP/RT/curie RAEB 45,XY,add(1)(q41),25,27, +mar [11]/ MLL ND A no no no
C 45,XY,add(1)q41,25,27,
t(12;20?)(p12;q12),+mar [11]
t-6 44/M Follicular ATII/Alk/Oncovin AML 46,del(X)(q23),Y,der?(6),t(2;6)(q12; MLL ND A no no no
NHL Alk/AT II/TBI/ q21),27,del(18?)(q12),add(20)(q12)
Alk Fluda but uncertain conclusion at diagnosis
t-7 73/M Multiple Alk/steroids/INF/ AML + 46–47,XY,27,28,+r+dm [20] MLL ND A no no no
myeloma AT II/BCNU Myeloma
t-8 72/M Follicular Alk/ATII/Fluda/ AML-M5 47,XY,del(7)(q21q32),+13 [11] MLL ND A yes no no
NHL Chlorambucil,
Rituximab/
Spleen RT
t-9 69/M Head and RT AML-M5 45,XY, 27 [12] MLL WT A no no no
Neck C.
t-10 57/M Bladder RT/SP MDS 46,XY, [14]/46–47,XY,del(7q-) [5] MLL ND A no no no
Cancer WCP 7
t-11 62/M Follicular Alk/ATII/INF/ AML-M5 NA# MLL ND A yes no no
NHL MethylGAG
Rituximab/skin RT
t-12 63/M NSCLC AT II/SP/RT AML 46 XY,t(8;21)(q22;q22) [1]/46 XY, MLL ND U no no no
t(8;21)(q22;q22),del(7)(q11q34) [13]
t-13 38/F Breast Alk/RT/ AML 46,XX,add(1)(q 3?) [25] MLL ND U yes no no
Cancer ATII/RT/AM
t-14 25/F Endometre Alk/AT II/SP, AML-M4 47,XX, +8 [14] MLL WT U yes yes yes
cancer Actinomycine
t-15 52/F Breast Alk/AT II/RT biphenotypic 48,XX,+8,t(9;22)(q34;q11),+17 [12] MLL ND U yes no no
Cancer AML-M4 WCP 8 +
WCP 17
BCR-ABL
fus
T yes no yes
T yes no yes
T yes no yes
t-19 55/F Breast Alk/ATII/RT/HT/ AML-M5 46,XX,t(9;11)(p21;q23) [21] MLL ND T yes no no
Cancer Tax
t-20 61/F Breast C. Alk/AT II/RT/HT AML-M5 46,XX,t(9;11)(p22;q23) [14] MLL sep T yes yes no
t-AML and p-AML aCGH
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potential candidate genes induced by AA or ATII implicated in
oncogenesis: 3) to perform a similar analysis for p-AML and 4) to
compare these two AML entities in our series and in the literature.
Materials and Methods
Patients
The patients were studied according to protocols approved by
the Institut Gustave Roussy (Villejuif, France) Ethics Committee.
Between 1995 and 2007, 30 t-AML and 36 p-AML with various
karyotype results were collected at disease onset. (table 1 and 2).
Cytogenetic analysis
Cytogenetic analyses were performed on metaphase spreads
obtained from tumor, bone marrow or blood. In each case, 20
RHG-banded metaphases were analyzed when possible.
Fluorescence in situ hybridization (FISH) studies
A set of commercial probes was used to search for abnormalities
such as WCP1, WCP2, WCP5, WCP7, WCP8, t(8;21) RUNX1-
ETO fusion probes (fp), t(9;22)BCR-ABL (fp), MLL dissociation
probes, WCP14, t(15;17) PML-RARA (fp), WCP17 (tables 1 and
2). They were used according to the manufacturer’s protocol
(VysisH or KreatechH).
Cell culture
Most samples were diagnosis bone marrow cells except for
patients t-4, t-9, t-11, t-17, t-19, t-26 and p-33 derived from whole
blood. After thawing, all t-AML samples were cultured for 24h
(20% fetal calf serum in RPMI 1640 with antibiotics) without
selecting CD34+ cells. The mononuclear cells were collected and
washed before DNA extraction. Bone marrow was cultured in the
same flask with the same media, to allow adherent cell
proliferation in order to obtain constitutional fibroblasts from
the patient. However, no adherent cells were obtained from this
procedure. Pooled commercial DNA (PromegaH) was thus used for
all t-AML and p-AML work in order to maintain a homogenous
process for the 64 AML.
Oligonucleotide aCGH
Tumor genomic DNA was isolated according to Qiagen
protocols with modifications [5]. Samples containing more than
60% of blasts were chosen in order to analyze a majority of
pathological cells. High-molecular-weight genomic DNA was
extracted from the cell lines with a DNeasy extraction kit (Qiagen).
Patient leukemia samples were analyzed using 244 K micro-
arrays (Agilent Technologies, Santa Clara, CA, USA). Only t-
AML were processed as dye-swap pairs. In all experiments, sex-
matched DNA from a pooled human female or male individual
(Promega, Madison, WI) was used as the reference. Oligonucle-
otide aCGH processing was performed as detailed in the
manufacturer’s protocol (version 4.0; http://www.agilent.com).
Data were extracted from scanned images using Feature
extractionH software (version A.8.5.3, Agilent). Raw data text files
from the latter were then imported for analysis into CGH
AnalyticsH 3.4.40. Aberrations were detected with the ADM2
Pts1 Age
2/ Primary
3 -P C T t 4 FAB5 Karyotype at diagnosis of t-AML FISH6 p-AML AML Allog.9 Survival.
Sex Cancer
3 - Type
7 Tt
8 12 month
t-21 60/F NHL Alk/AT II, Autograft AML-M5 46,XX,t(9;11)(p22;q23) [12] MLL sep T yes no no
t-22 19/M Osteo- Alk/AT II/SP AML-M5 46,XY,t(9;11)(p21;q23) [8]/ MLL sep T yes no yes
sarcoma 46,XY,t(9;11)(p21;q23),+8[ 1 0 ]
t-23 22/F HL Alk/ATII/Bleo/ AML-M5 46,XX,t(11;19)(q23;q13) [12] MLL sep T yes no dead at
Oncov diagnosis
t-24 44/F Ovarian Tax/SP/AT II/ biphenotypic
AML
46,XX, [2] MLL sep T yes no no
cancer Iressa
t-25 64/F Ovarian Tax/SP/Iressa MDS 46,XX [17] MLL WT U no no no
cancer
t-26 51/F Anal + RT, Alk/AT II/RT AML 46,XX [5] MLL WT U yes no no
Breast C
t-27 47/F Breast C. Alk/AT II/RT/HT AML-M2 46,XX [20] MLL WT U yes no U
t-28 54/F Breast C Alk/AT II/RT AML-M1 46,XX [16] MLL WT U yes yes yes
t-29 71/M Prostatic RT AML 46,XY [20] MLL WT U no no no
cancer.
t-30 67/M Head and AT II/SP/Bleo/RT AML-M5 46,XY [21] MLL WT U yes no no
Neck C.
1=patients. 2=age at diagnosis of AML. 3=Primary cancer; NHL: Follicular non hodgkin lymphoma, NSCLC: Non small cell lung cancer, VLSL: Villositary lymphocyte
splenic lymphoma. 4=Primary cancer treatment; Alk: alkylating agent, RT: radiotherapy, AT II: anti-topoisomerase II, AM: anti-metabolite, brachy: brachytherapy, Clo:
Chlorambucyl, Tax: taxane, Fluda: fludarabine, SP: platinium, Bleo: bleomycin, HT: hormonotherapy, INF: interferon, Rit: Rituximab, RT: Radiotherapy, TBI: Total Body
Irradiation, Oncov: Oncovin, A: alkylating-agent-inducing type, T: anti-topoisomerase-inducing type, U: undetermined. 5=FAB classification: biph=biphenotypic.
6=FISH column: MLL WT=MLL Wild Type, MLL R=MLL rearranged, ND=Not Done. 7=Type of t-AML; A: alkylant induced, T anti-topoisomerase-induced. 8=AML
treatment. 9=Allograft as treatment.
#This patient had secondary MDS for several years before the leukemia, with transitory partial monosomy 7, that had disappeared a year later, two years later the t-AML
appeared.
doi:10.1371/journal.pone.0016623.t001
Table 1. Cont.
t-AML and p-AML aCGH
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Patients Age
1/ FAB Karyotype FISH Allograft Survival
Sex duration .
12 months
p-1 68/F M1 45,XX,27 N D N oi n f o N oi n f o
p-2 34/M M6 45,XY,27N D n o n o i n f o
p-3 66/M M1 48,XY,+8,+13 ND No Yes
p-4 54/F M5 47,XX,+i(21q) ND Yes Yes
p-5 32/M M5 47,XY,t(2;14)(q21;q32),+4 wcp2, wcp14 No No
p-6 44/F M5 46,XX,der(5)t(1;5)(q32;q35),inv(9)(p12q13)[20]. MLL WT, wcp1, No No info
ish(5p15,5q31)62,add(5)(q35?)(wcp1+) wcp5,wcp17
p-7 68/M M5 46,XY,del(7)(q21q31),der(9)(WPC9+),?der(11)(q23)/46,XY[2] MLL WT No No
p-8 25/F M3 46,XX,t(15;17)(q22;q21) PML-RARA fus
p-9 46/F M3 46,XX,t(15;17)(q22;q21) PML RARA fus No No info
p-10 46/F M3 46,XX,t(15;17)(q22;q21) PML RARA fus No Yes
p-11 27/M M3 46,XY,i(3)(p10),i(3q),t(15;17)(q22;q21) PML RARA fus No Yes
p-12 47/M M3 46,XY,t(15;17)(q22;q21) PML RARA fus No No
p-13 73/M M3 46,XY,t(15;17)(q22;q21) PML RARA fus No Yes
p-14 35/M M3 46,XY,t(15;17)(q22;q21) PML RARA fus No Yes
p-15 57/M M3 46,XY,t(15;17)(q22;q21) PML RARA fus No Yes
p-16 54/M M4 46,XY,t(16;16)(p13;q22) CBFB sep Yes No
p-17 26/M M4Eo 46,XY,t(16;16)(p13;q22) ND Yes Yes
p-18 19/M M2 45,XY,t(8;21)(q22;q22),del(9)(q31q34) ND No Yes
p-19 37/M M1 45,XY,t(9;11)(p22;q23),del(7)(p12;p21) MLL sep No Yes
p-20 25/M M1 46,XY,t(9;11)(p22;q23) MLL sep Yes Yes
p-21 80/M M1 46,XY[3]/50–53,XY,21,23,24,215?,221,+7 to 10 mar ND No No
p-22 42/M M1 46,XY,t(3;5)(q25;q34),del(4)(q26),der(12)t(4;12) WCP(3; 4) Yes Yes
(q28?;p12),der(18)t(12;18)(p12;q21),mar? WCP(5; 12)
p-23 30/M M5 46,XY,t(11;12)(q13;p13)[2]46,XY,id,der(1)t(1;1) ND No No
(p16;q12)[1]/46,XY,id,der(7)t(1;7)(q12;q36)[1]/
46,XY,id,der(9)t(1;9)(q12;p24)[2]46,XY,id,der(14)
t(1;14)(q12;p10)[2]46,XY,id,der(20)t(1;20)(q12;p12)
[1]46,XY,id,der(20)t(1;20)(q12;q13)[2]46,XY,id,
der(21)t(1;21)(q12;q10)[3]
p-24 71/M M2 43–46,XY,22,25,27,216,+mar1,+mar2,+mar3, +mar4, ND No No
variations
p-25 63/F M2 46,XX ND No Yes
p-26 52/F M2 46,XX MLL WT Yes Yes
p-27 23/F M2 46,XX MLL WT No Yes
p-28 23/F M5 46,XX MLL WT Yes Yes
p-29 45/F M5 46,XX ND No No
p-30 73/F M5 46,XX ND No No
p-31 31/M M0 46,XY MLL WT No No info
p-32 75/M M1 46,XY MLL WT No No
p-33 41/M M1 46,XY MLL WT Yes No info
p-34 48/M M2 46,XY MLL WT Yes Yes
p-35 38/M M2 46,XY MLL WT No No
p-36 63/M M4 46,XY ND No No
1=age at diagnosis of AML. FAB column: FAB classification. FISH column: MLL WT=MLL Wild Type; MLL sep=MLL rearranged (separated); PML-RARA fus=fusion of
PML and RARA gene; WCP=whole chromosome paint; ND=Not Done.
doi:10.1371/journal.pone.0016623.t002
t-AML and p-AML aCGH
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abs(log2Ratio) .0.3. Aberration segments were individually
reviewed using build 35, hg18 from the UCSC Genome browser
[6]. Anomalies that were localized to regions with high-copy
repetitive or GC-rich DNA sequences including telomeric regions
were excluded. We defined gains and losses for the oligonucleotide
dataset as a linear ratio $1.2 or #0.8 respectively. High and low-
level amplification events were defined as a linear ratio $4o r
between ,2 and ,4 respectively. The data are described in
accordance with MIAME guidelines and have been deposited in
ArrayExpress under accession number E-TABM-1014.
Results
Copy Number Variations (CNV)
As no paired DNA had been obtained, Copy Number
Variations (CNV) were distinguished from Copy Number
Abnormalities (CNA) based on various criteria: i) sequence size
below 2 Mb; ii) the presence of repetitive identical breakpoints
between patients; iii) the genes involved such as olfactory receptor
genes, the NF1P1 locus or GSTT1 (chromosome 22) and iv)
consultation of the Database of Genomic Variants [7]. Many
Mendelian CNVs, that are present throughout the entire genome
[8], were seen in the two AML samples (table 3). Together with
classic genes, four microRNA embedded in CNV regions were
found: mir-570 in 3q29 within MUC20, mir-1268 in 15q11 within
NF1P1, BCL8 and olfactory receptors, mir-1233 in 15q14 within
GOLGCABB, and mir-1826 in 16p11.2 within TP53TG3
HERC2P4 (table 3).
Deletions inside immunoglobulin gene (IG) clusters, consecutive
to VDJ rearrangement were observed mainly in t-AML. These
illegitimate recombinations were considered as acquired CNVs
[5], characteristic of the malignant clone. In t-AML, four losses
were located in 2p11 in IGLK and 9 in 14q32.3 in IGH. Two t-
AML were bi-phenotypic acute leukemia (cases 2 and 7). In three
cases (t-15, t-17 and t-25), both genes were rearranged (table 4).
No relationships were observed with MLL or other translocations.
In p-AML (table 5), only 2 rearrangements were observed: on
IGLK (case p-21) and on IGH (case p-24). No rearrangement of
IGLL on 22q11 was observed. The difference in the proportion of
IG rearrangements in t-AML compared to p-AML was statistically
significant with a p,0.002.
Table 3. Germinal and immunoglobulin genes related CNVs.
Location Some CNV genes miRNA
Germinal CNVs
21p36.13 ,16.71–17.14. CROCC MSTP9 ESPNP
21q21.3 ,150.82–150.84. NLCE3C
21q23.3 ,159.75–159.90. FCGR2A FCGR2B FCGR3A HSPA6
21q44 ,246.79–246.86. OR2T34 OR2T10 OR2T11
+/23q29 ,196.90–196.96. MUC20 mir-570
+/24q13.2 ,69.05–69.16. UGT2B17
+5p15.33 ,0.76–0.87. ZDHHC11
26p25.3 ,0.20–0.32. DUSP22
+/26p21.2 ,32.56–32.72 HLA-DQA1 HLA-DRB1 HLA-DRB5 HLA-DRB6
+/28p11.3 ,39.35–39.50. ADAM3A
210q11.22 ,46.37–47.73. ANXA8 PPYR1 GPRIN2 SYT15 ANTXRL
+11q11 ,55.12–55.20. OR4P4 OR4C11 OR4S2 OR4C6
+12p12 ,19.36–19.46. PLEKHA5
+/214q11.2 ,18.62–19.49. OR4K5 OR4K1 OR4N2 OR4K2 OR4Q3 OR4M1
+/215q11.2 ,18.65–20.08. BCL8 NF1P1 OR4N4 OR4M2 mir-1268
+/215q14 ,32.51–32.62. GOLGABB mir-1233
+/216p11.2 ,31.86–33.53. TP53TG3 SLC6A10P HERC2P4… mir-1826
+17q21.31 ,41.52–41.57. KIAA1267
217q21.31 ,41.55–42.04. NSF LRRC37A ARL17P1 KIAA1267 LRRC37A2
219q13.2 ,48.20–48.43. PSG1 PSG3 PSG6 PSG7 PSG11
+/222q11.23 ,22.65–22.72 GSTT1.
Immunoglobulin genes related CNVs
22p11.2 ,89.10–89.26. IGKC IGKV1-5 IGKV3D-15 IGKV1D-13 IGKV3-20 IGKV2-24
+/27p14.1,38.22–38.41. TRGC2 TRGV5 TRGV7 TRGV9 STARD3NL
+/214q11.2 ,21.43–22.04. TRA@ TRD@ TRDV1 TRAV20 TRAJ17 TRAC
214q32.33 ,105.13–106.00. IGH@ IGHA1 IGHA2 IGHG1 IGHG2 IGHG4 IGHV4-31 C14orf81
The CNVs are either lost or gained as indicated by a ‘‘2’’ or a ‘‘+’’. Locations on chromosomes are described according to the ISCN 2009 with slight modifications:
sequence numbers are included between ,. and expressed in Mb, with a resolution of 10kb. Column 2: coding genes included in the CNVs: Column 3; miRNA genes
included in the CNVs.
doi:10.1371/journal.pone.0016623.t003
t-AML and p-AML aCGH
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Patients Gains Losses Revised karyotypes
t-2 +14q11.2q12,24,09–26.24.[1.23] 21q44,241.94–247.19.[0.61] 44,XX,21q44,25q14.3q35,27,27q33q34,212p11.2p13.2,
+14q12q13.3,29.52–35.74.[1.26] 25q14.3q35,85.18–167.84.[0.58] 212p11.2q12,212q13.1,212q13.3q22,212q23.3,
+14q21.1q21.2,41.52–44.69.[1.23] 27pterp22.3,0.14–2.67.[0.65] 214q12,+14q12,214q12,+14q12q13.3,
+14q21.3q22.1,47.25–52.51.[1.54] 27p21.3,8.21–11.79.[0.64] 214q21.2,+14q21.1q21.2,214q21.2,+14q21.3q22.1,
27p15.2q14.3,27.40–33.28.[0.67] 218q11.1qter,218q11.2q12.1,
27p14.1q33,39.89–135.74.[0.63] 218q22.3q23
27q33q34,135.74–137.48.[0.16]
27q34qter,137.48–158.76.[0.60]
212p13p11.2,11.27–25.37.[0.61]
212p11.2q12,32.77–37.09.[0.65]
212q13.1,47.09–49.44.[0.66]
212q13.3q22,55.30–92.75.[0.63]
212q23.3,105.58–107.51.[0.68]
214q11.2,23.73–24.07.[0.70]
214q12,26.25–27.10.[0.65]
214q21.2,35.77–37.62.[0.66]
214q21.2,44.69–45.26.[0.66]
218q11.1q11.2,16.79–21.74.[0.59]
218q11.2q12.1,21.74–24.41.[0.22]
218q12.1q22.3,24.41–71.05.[0.59]
218q22.3q23,71.06–71.76.[0.23]
218q23,71.76–76.11.[0.59]
t-24 +17q11.1qter,22.80–78.65.[1.39] 22p11,89.65–91.05.[0.62]* 46,XX,t(11;?)(q23;?),i(17)(q10),219p13.3,+19p13.3
+19p13.3,4.96–6.82.[1.44] 217pterp11.2,0.28–21.22.[0.63]
219p13.3,0.21–4.96.[0.60]
t-8 +13q11qter,18.36–114.10.[1.46] 27q31.1q36.1,107.67–150.28.[0.55] 47,XY,2Xp11.4,27q31.1q36.1,+13,221q22.1
221q22.1,35.01–35.60.[0.11]
2Xp11.4,39.25–39.85.[0.16]
t-13 +2p16.1p25.3,0.02–54.88.[1.46] 21q42.3.q44,233.13–247.19.[0.53] 46,XX,der(1)t(1;2)(q42.3;p16.1),210q11.2
210q11.2,45.53–47.97.[0.78]
t-30 22p23.3,25.31–25.60.[0.50] 46,XY,22p23.3
214q32.3,105.96–106.00.[0.65]*
t-15 +8pterqter,0.16–146.26.[1.31] 22p11,88.98–91.05.[0.46]* 46,XX,+8,t(9;22)(q34;q11),+17
+17pterqter,0.02–78.65.[1.31] 24q31.2,146.62–146.67.[0.68]
214q32.3,105.40–106.15.[0.34]*
t-4 +2q14.3q32.3,128.11–193.87.[1.34] 21p36.11,26.73–27.04.[0.64] 46,XX,dup(2)(q14.3q32.3),t(5;13)(p15;q14)
+7q11.2q36.3,61.46–158.81.[1.65] 21q43,237.92–238.50.[0.62] 25q31.3q32,+i(7)(q10),der(7)t(7;15)(q10;q21.3),
+12p12.1 p11.2,24.32–30.60.[1.37] 25q31.1q33.1,142.91–148.19.[0.63] der(12)t(12;17)(p12.1;q11),+12p11.2p12.1,
27p11.1p22.3,0.14–57.89.[0.65] 215pterq21.2, 217p11.2p13.3,217q23.2
212pterp12.1,0.05–21.96.[0.63]
214q32.3,105.13–105.84.[0.68]*
215q11.2q21.3,20.24–55.80.[0.65]
217p13.3p11.2,0.02–22.07.[0.65]
217q22,51.84–54.75.[0.64]
t-16 +7p15.2,27.15–27.18.[1.33] 46,XX,+7p15.2,+8q24.2q24.3,inv(16)(p13;q22)
+8q24.2q24.3,139.48–140.18.[1.46]
t-23 +4q35.1q35.2,187.17–187.37.[1.49] 214q32.3,106.21–106.25.[0.66]* 46,XX,+4q35.1q35.2,t(11;19)(q23;q13)
t-17 +7p15.2,27.15–27.18.[1.26] 22p11,89.10–89.89.[0.70]* 23p12.3p14.1,+7p15,t(15;17)(q22;q21)
+
+6q27,168.12–168.84.[1.20] 23p12.3p14.1,69.07–79.19.[0.54] .ish(PML;RARA)
214q32.3,105.85–105.89.[0.59]*
t-AML and p-AML aCGH
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t-29 214q32.3,105.94–106.00.[0.66]* 46,XY,221q22.1
221q22.1,34.98–35.29.[0.59]
t-3 +8q24.3,143.73–143.90.[1.50] 214q32.3,104.96–105.22.[0.76]* 46,XX,t(1;17)(p36;?),t(7;?)(p15;?),+8q24.3,
t(7;10;17)(?;p11;q21;?)
t-26 +2q11.2,98.43–98.63.[1.42] 46,XX,+2q11.2
t-12 +21q22.1qter,35.07–46.91.[1.19] 27q22.1q36.3,101.85–158.79.[0.80] 46,XY,27q21.2q36.3,t(8;21)(q22;q22),+21q22.1qter
t-9 +4p16.3,1.20–1.30.[1.38] 27pterqter,0.14–158.76.[0.56] 45,XY,+4p16.3,27
+6q27,168.08–168.32.[1.50]
t-11 221q22.12,35.11–35.15.[0.68] 46,XY,221q22.12
t-14 +7p15.2,27.15–27.18.[1.38] 214q32.3,105.96–106.00.[0.60]* 47,XX,+7p15,+8,217q11.2
+8pterq24.3,0.16–142.23.[1.35] 217q11.2,25.96–27.38.[0.72]
+8q24.3,142.23–145.81.[1.52]
+8q24.3,145.81–146.26.[1.35]
t-1 25q15qter,94.36–177.87[0.79] 57,XXX,+1,+4,del(5)(q15q33)62,27,+8,+9,+der(11),
+13, +14,217,+18,+19, 220,+22,+mar
t-5 +5p15.2p14.3,10.78–21.71.[1.27] 23p14.1p12.3,69.67–80.18.[0.54] 46,XY,23p12.2p14.1,25p15.2pter,+5 p14.3p15.2,
+5p13.3q11.2,31.24–53.59.[1.31] 25pterp15.2,0.09–10.76.[0.57] +5p12q12.3,25q12.3qter,27p11.1p22.3,
+21q22.1,36.40–36.53.[1.60] 25q12.3qter,65.23–180.64.[0.57] 27q21.3q32.1,212p13.1p13.2,+21q22.1
27pterp11.1,0.14–57.66.[0.57]
27q21.3q36.3,97.13–158.76.[0.57]
212p13.2p13.1,11.82–13.33.[0.62]
t-10 +1q44,246.44–247.06.[1.32] 27p22.2,3.02–3.12.[0.48] 46,XY,+1q44,27p22.2,27q11.2,27q21.3q22.1
27q11.2,64.40–75.85.[0.77]
27q21.3q22.1,97.69–101.88.[0.77]
t-7 +9q34.3,135.98–139.80.[1.30] 27pterqter,0.14–158.81.[0.79] 45,XY,27,+9q34.3,+12p13.1,+12p11.1,212q11q12,-
+12p13.1,14.25–14.61.[1.36] 212q12,36.73–42.14.[0.65] 212q13.1,+12q13.12q14.3,217p11.2p13.3,
+12p11.1,31.55–34.64.[1.34] 212q13.1,45.33–47.69.[0.68] 221q21.1q21.2,+21q21.2q21.3,221q22.11q22.12,
+12q13.1q14.3,47.69–51.83.[1.42] 217pterp11.3,0.02–21.23.[0.78] +21q22.12q23,221q22.3
+12q14.1q14.3,58.80–64.31.[1.33] 221q21.1q21.2,19.84–23.05.[0.65]
+21q21.2q21.3,23.17–30.35.[1.42] 221q22.1,34.38–36.12.[0.66]
+21q22.1q22.3,36.20–43.01.[1.58] 221q22.3,43.02–43.08.[0.65]
t-6 27pterqter,0.14–158.76.[0.70] 45,XY,t(2;6)(q12;q21),27
t-22 +2p25.2,2.54–3.57.[1.37] 46,XY,+2p25.3,+8,t(9;11)(p21;q23)
+8pterqter,0.16–146.26.[1.40]
t-19 +7p15.2,27.15–27.18.[1.40] No CNA 46,XX,+7p15.2,t(9;11)(p22;q23)
t-21 No CNA No CNA 46,XX,t(9;11)(p22;q23)
t-20 No CNA No CNA 46,XX,t(11;19(p22;q23)
t-18 No CNA 214q32.3,105.94–106.00.[0.64]* 46,XX,t(15;17)(q22;q21)
t-25 No CNA 22p11,89.10–91.05.[0.69]*. 46,XX
214q32.3,105.96–106.00.[0.61]*
t-27 No CNA No CNA 46,XX
t-28 No CNA No CNA 46,XX
Column 2 and 3: The CNA are either lost or gained as indicated by a ‘‘2’’ or a ‘‘+’’; locations on chromosomes are described according to the ISCN 2009 with slight
modifications: sequence numbers are included between ,. and expressed in Mb, with a resolution of 10kb; linear ratios are written between brackets after an ‘‘6’’;
CNAs with a linear ratio .2 (low level of amplification) or losses ,0.25 are labeled in bold and italics; ‘‘*’’ indicates CNA that are probably part of a rearrangement of
the immunoglobulin genes. They have not been included in the synthetic karyotypes because they could be considered as an acquired CNV which is characteristic of
monoclonal proliferation.
Column 4: In bold are new data or those modified by aCGH in the synthetic karyotypes; CNAs that were contiguous but whose ratios were not too different were fused
to express overall chromosome abnormality for readability.
doi:10.1371/journal.pone.0016623.t004
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p-24 +1p36.3,1.52–7.56.[1.26] 22pterp22.3,0.02–32.60.[0.66] 46,XY,+1p34.2p36.3,22pterp22.3,22p14p13.3,
+1q21q22,153.19–154.64.[1.67] 22p14p13.3,68.01–71.72.[0.66] 22q35qter,+3p21.3, 23p21.3p22.2,+4p16.3,
+3p21.3,50.26–50.29.[2.54] 22q35qter,219.02–242.39.[0.66] 25q14.2q33.3,27p15.2p15.3,27q11.2,27q21.1q22.2,
+3p21.3,52.29–52.31.[4.00] 23p22p21.3,38.35–49.66.[0.66] 27q31.3q36.3,+15q11.2,+15q22.2q26.2,
+4p16.3,0.99–1.65.[1.61] 25q14.2q33.3,82.18–158.75.[0.61] +15q23,215q26.2q26.3,216p13.3q23.1,
+15q22.2q23,56.84.18–67.10.[2.05] 27p15.2p15.3,19.64–26.31.[0.63] +16q23.3q24.3,217p11.2q12,217q21.31q21.3,
+15q23,67.44–68.37.[3.64] 27q11.22q11.23,69.84–72.44.[0.65] +19p13.3p13.1, +20p12.3p13, +21q22.1q22.3,+22q13.1
+15q24.1,70.42–72.67.[2.89] 27q21.12q22.2,87.65–105.96.[0.71]
+15q24.1q26.2,72.70–94.54.[1.30] 27q31.32q36.3,123.35–158.81.[0.64]
+16q23.3q24.3,82.61–88.67.[1.8] 214q32.3,105.602105-70.[0.74]*
+19p13.3p13.1,0.64–19.72.[1.41] 215q26.2q26.3,94.55–100.21.[0.75]
+20p12.3p13,0.27–9.14.[1.26] 216p13.3q23.1,15.38–78.80.[0.74]
+21q22.1,33.30–37.23.[1.79] 217p11.2q12,0.18–29.54.[0.65]
+21q22.1,37.24–38.54.[2.5] 217q21.3q21.33,38.29–46.94.[0.66]
+21q22.1,38.54–39.38.[3.00]
+21q22.2q22.3,39.40–43.22.[2.18]
+21q22.3,43.23–46.89.[1.70]
+22q13.1,35.86=37.20.[1.33]
p-21 +3p14.3p14.2,57.97–62.19.[1.48] 21q21.1q44,147.21–247.19.[0.62] 50–53,XY,21q21.1q44,22p24.3,
+3p14.2p14.1,63.60–64.29.[1.31] 22p11.2,89.38–91.05.[0.61]* 23p12.1p14.1,+3p14.1,23p14.1,+3p14.1p14.2,
+3p14.1,64.32–65.50.[4.61] 22pterp24.3,0.02–16.22.[0.61] +3p14.2p14.3,23p14.3p24.3,+3p11.2qter,
+3p14.1,66.40–67.67.[4.71] 23 p24.3p14.3,0.03–57.40.[0.63] 24q22.1q27,29q22.3q31.1,
+3p11.2qter,89.28–199.32.[1.35] 23p14.2,62.20–63.58.[0.60] +21q11.2q21.1,
+21q11.2q21.1,14.29–17.97.[5.46] 23p14.1,65.51–66.11.[0.60] +21q22.1qter
+21q22.1q22.3,38.27–43.54.[5.45] 23p14.1p12.1,67.68–86.30.[0.67]
+21q22.3,43.59–45.12.[2.11] 24q22.1q27,88.94–123.72.[0.61]
+21q22.3qter,45.12–46.91.[1.7] 29q22.3q31.1,93.92–103.86.[0.63]
p-22 24q28.2q28.3,130,24–134,36.[0,55] 46,XY,t(3;5)(q25;q34),del(4)(q28.2q28.3),
212p12.1p13.2,11,40–21,20.[0,55] der(12)t(4;12;18)(q28?;p12;q21),
218q21.2,48,99–51,05.[0,55] 212p12.1p13.2,218q21.2,218q22.3q23
218q22.3q23,69,56–76,03.[0,55]
p-23 +1q23.2qter,158.48–247.17.[1.24] No CNA 46,XY, t(11;12)(q13;p13)/46,XY,id,der(1)t(1;1)(p16;q12)/
46,XY,id,der(7)t(1;7)(q12;q36)/
46,XY,id,der(9)t(1;9)(q12;p24)/46,XY,id,
der(14)t(1;14)(q12;p10)/46,XY,id,der(20)t(1;20)
(q12;p12)/46,XY,id,der(20)t(1;20)(q12;q13)/
46,XY,id,der(21)t(1;21)(q12;q10),+1q23.2qter
p-5 +4pterqter,0.06–191.02.[1.43] No CNA 47,XY,t(2;14)(q21;q32),+4
p-32 23p21.3p21.3,44,20–49,02.[0,59] 46,XY,23p21.3
p-6 +1q32.1qter,201.31–247.10.[1.39] 46,XX,der(5)t(1;5)(q32;q35),inv(9)(p12q13)
p-1 27,0.14–158.76.[0.61] 45,XX,27
p-2 +Xp22.2,15.95–16.61.[2.04] 27,0.14–158.76.[0.55] 45,XY,+Xp22.2,27,222q11.2
222q11.2,21.36–21.41.[0.52]
p-7 +11q24.2qter,124.85–134.43.[1.23] 27q31.2qter,115.49–158.78.[0.77] 46,XY,27q31.2q36.3, +11q24.2q25
p-3 +8pterqter,0.16–146.25.[1.27] 22p11.2,88.93–89.14.[0.69]* 48,XY,+8,+13
+13pterqter,18.31–114.12.[1.28]
p-18 No CNA 28q21.3q22.1,93.15–94.17.[0.63] 46,XY,t(8;21)(q22;q22),del(8)(q21.3q22.1),29q12q31.1
29q12q31.1,67.20–104.45.[0.62]
p-13 +17q21.2,35.76–35.84.[1.49] No CNA 46,XY,t(15;17)(q22;q21),+17q21.2
p-4 +21q11.2qter,14.31–46.91.[1.77] No CNA 47,XX,+i(21q)
t-AML and p-AML aCGH
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Karyotypes and aCGH were well correlated, with few exceptions.
Ninety-six unbalanced chromosomal abnormalities previously unde-
tected by mitotic karyotypes, were detected after high resolution
aCGH (tables 1, 2, 4 and 5). Most of the additional abnormalities
were too small to be detected by karyotypes. Some revealed masked
rearrangements (Figure 1). In case t-1, the discrepancy between the
karyotype and aCGH was probably due to a combination of
hyperploidy, genetic heterogeneity and the presence of normal cells
resulting in aCGH detection of only the del(5q).
In both groups of AML, 25 cytogenetically balanced translocations
(table 1, 2 tables 4 and 5) did not show any cryptic rearrangement
(gain or loss) at their breakpoint locations. In 5 cases (t-3, t-5, t-12, p-
18, p-13), a CNA was found near the breakpoints. Patient t-3 was
considered as having multiple balanced translocations that could not
be further analyzed due to insufficient material. Patient t-5 had a
poorly defined translocation implicating 12p and according to aCGH
analysis, a small loss began in the middle of ETV6, suggesting a
rearrangement of this gene. Patient t-12, had a standard t(8;21) and
following ‘‘good practice’’ rules, no further investigation was initially
performed. aCGH revealed a duplication of 21q22.1qter that was
confirmed by FISH as another translocation or insertion on an
unidentified chromosome. The unbalanced translocation breakpoint
was 30 Kb centromeric to the 39 end of RUNX1 suggesting a
possible double event. Patient p-18, with a t(8;21) p-AML, had a 1Mb
loss that included the first two exons of RUNXT1 on 8q21.3. Patient
p13 had a t (15.17) accompanied by a small duplication of the
telomeric part of RARA and of the TOP2A genes (table 5).
In some cases the confrontation between aCGH and the karyotype
allowed us to better define the previously diagnosed rearrangements.
In patient t-13, an add(1)(q3?) was found in the morphological
karyotype. With aCGH, it was concluded that it resulted from an
unbalanced translocation der(1)t(1;2)(q42.3;p16.1). The breakpoint
was virtually cloned from the arrays: on 1q42.3,231.374.,i tw a s
sitting in the middle of PCNXL2, between exons 11 and 12. On
2p16.1,54.943., it was lying in an EML6 gene in the vicinity of
exon 12 of the gene. P-22, a primary AML with a t(3;5), had a loss of
10Mb of 12p13 secondary to a additional complex translocation
encompassing ETV6 and CDKN1B (table 5).
t-AML
All patients (excepted three who had received radiotherapy
alone) had been treated with multi-agent chemotherapy (AA and
ATII) combined or not with radiotherapy. Thus, the type of
induction mechanism was most of the time, deduced from the
observed chromosomal abnormalities (table 1): 9 cases were
probably AA induced, 9 were ATII-induced and in 12, the
mechanism could not be determined because CNA categorization
was indistinguishable between t-AML induced by AA or by ATII.
The medium time elapsed between cancer therapy and the
Patients Gains Losses Revised karyotypes
p-8 No CNA No CNA 46,XX,t(15;17)(q22;q21)
p-9 No CNA No CNA 46,XX,t(15;17)(q22 ;q21)
p-10 No CNA No CNA 46,XY,t(15;17)(q22;q21)
p-11 No CNA No CNA 46,XY,t(15;17)(q22;q21)
p-12 No CNA No CNA 46,XY,t(15;17)(q22;q21)
p-14 No CNA No CNA 46,XY,t(15;17)(q22;q21)
p-15 No CNA No CNA 46,XY,t(15;17)(q22;q21)
p-16 No CNA No CNA 46,XY,t(16;16)(p13;q22)
p-17 No CNA No CNA 46,XY,t(16;16)(p13;q22)
p-19 No CNA 214q32.3,105.02–105.04.[0.76]* 45,t(9;11)(p22;q23),del(7)(p12;p21)
p-20 No CNA No CNA 46,XY, t(9;11)(p22;q23)
p-25 No CNA 214q32.3,105.96–105.94.[0.61]* 46,XX
p-26 No CNA No CNA 46,XX
p-27 No CNA No CNA 46,XX
p-28 No CNA No CNA 46,XX
p-29 No CNA No CNA 46,XX
p-30 No CNA No CNA 46,XX
p-31 No CNA No CNA 46,XY
p-33 No CNA No CNA 46,XY
p-34 No CNA No CNA 46,XY
p-35 No CNA No CNA 46,XY
p-36 No CNA No CNA 46,XY
Column 2 and 3: The CNA were either lost or gained as indicated by a ‘‘2’’ or a ‘‘+’’; the locations on the chromosomes are described according to the ISCN 2009 with
slight modifications: sequence numbers are included between ,. and expressed in Mb, with a resolution of 10kb; linear ratios are written between brackets after an
‘‘6’’; CNAs with a linear ratio .2 (low level of amplification) or losses ,0.25 are labeled in bold and italics; ‘‘*’’ indicates CNA that are probably part of a rearrangement
of the immunoglobulin genes. They are not included in the synthetic karyotypes as they could be considered as an acquired CNV characteristic of monoclonal
proliferation.
Column 4: In bold are new data or those modified by aCGH in the synthetic karyotypes; CNAs that were contiguous but whose ratios were not too different were fused
to express overall chromosome abnormality for readability.
doi:10.1371/journal.pone.0016623.t005
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respectively.
Twenty-five patients (80%) with 104 CNA exhibited 41 gains
and 63 losses (table 4). The mean number per total case number
was 3.46. Six patients with a normal karyotype had at least one
CNA. Six patients (20%) had no CNA, 3 had a normal
karyotype and the 2 others had a balanced translocation (one a
t(15;17) and one a MLL rearrangement). The mean CNA length
was 4.1Mb for the t-AML patients with at least an unbalanced
rearrangement.
The twelve losses in the immunoglobulin genes (IG) on 2p11
and 14q32.3 were considered as a special category of CNA.
Among the 8 patients with IG rearrangements, 2 had bi-
phenotypic leukemia and the others had various forms of AML.
p-AML
Among 36 patients, 12 had a normal karyotype, 4 exhibited an
anomaly on chromosomes 5 or 7. A t(15;17)(q22;q21), character-
izing AML-M3, was present in 9 cases (table 2).
In p-AML, 64 CNAs were observed (table 5) with 30 losses and
34 gains while the mean number was 1.78. Twenty-two patients
had no CNA, 11 had a recurrent balanced translocation while the
11 others had a normal karyotype. The mean number of CNA
among p-AML patients with unbalanced rearrangements was
2.66. This value was due to 4 patients with very complex genomic
rearrangements (.8 chromosomal abnormalities).
Minimal Critical Regions (MCR)
A MCR was defined as such if 2 cases or more shared a
common genomic location. Twelve MCRs were observed in t-
AML and eight in p-AML (table 6).
The size of MCRs was smaller in t-AML, with a minimum of
0.04 Mb compared to p-AML with a minimum of 0.95 Mb. The
longest MCR in t-AML was 36.44 Mb, of the same order of
magnitude as in p-AML where it was 45.69 Mb.
Unique CNA
These single cases were of various sizes, from 0.04Mb to
26.89 Mb. Most of them were small and not known as
polymorphisms. They are detailed in table 7.
Discussion
The CNVs
As we were obliged to use a pool of normal DNA as a reference,
Mendelian CNVs that are present throughout the entire genome [8],
were revealed by the 244K aCGH (table 3). They were identified in
the Toronto Database [7] in order to avoid including them in the
analysis of somatic CNA. However, as a relationship between some
CNVs and malignancy has already been suggested [9], several of
them wereretained in a separate table(table 3). For examplea GSTT
gene cluster was reported to be a susceptibility co-factor in cancer
[10,11,12]. It is noteworthy that several miRNA, i.e. mir-570, mir-
1268, mir-1233 and mir-1826 were found embedded in CNVs, with
a possible multigene regulatory effect, as reported by Lin [13].
High resolution aCGH allowed us to study the whole set of IG
gene rearrangements [5]. VDJ rearrangement in immunoglobulin
genes (IG) has been described in AML [14,15] and associated with
MLL rearrangements [16]. The two series of patients (t-AML vs p-
AML), were found to be significantly different, with a p value of
,0.002. The fact that a quarter (8/30) of t-AML exhibited a VDJ
rearrangement suggests that the transformed cells are often
multipotent in these diseases.
The CNAs
The acquired chromosomal abnormalities detected by morpho-
logical cytogenetics were quite similar in t-AML and p-AML. The
CNA patterns were well correlated between the morphological
cytogenetics and aCGH. Their frequency was increased after high
resolution aCGH. Losses were more frequent than gains in both
series. The number of CNAs was higher in t-AML (n=104, mean
Figure 1. Details of critical rearrangements concerning MCRs. A=gain on 8q24.3 in a t-AML; B=loss of 12 p13 in t-AML (patients t-4 and t-5);
C loss of 3p21.3 in a p-AML.
doi:10.1371/journal.pone.0016623.g001
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found here is of the same order of magnitude than that reported
elsewhere [17,18,19,20]. Subcytogenetic CNA were present in half
of the t-AML with normal karyotypes (table 4) while only 1 case (p-
32) was observed in p-AML (tables 5 and 7). These findings are in
accordance with the role of cytotoxic drugs in oncogenesis in t-
AML [4,21].
Twenty-five balanced translocations remained undetected
(tables 4 and 5). No deletion or amplification at the breakpoint
was observed in the five t-AML, nor in the two p-AML cases
with rearranged MLL. The exceptions were two t(8;21)
complex translocations resulting in detectable quantitative
CNA at their breakpoints. In case t-12, a t-AML, a distal
trisomy 21 began at the 59 extreme part of RUNX1
Table 6. Minimal Critical Region in the two groups of patients.
MCR (localization by aCGH) Patients Size (Mb) Possible genes
t-AML
21q44 ,241.94–247.19. t-2, t-13 5.25 .25 genes among them SMYD3
23p14.1p12.3 ,69.67–79.19. t-5, t-17 9.52 MITF FOXP1 EIF4E3 GRP27 PROK2 RYBP
SHQ1 PPP4R2 PDZRN3 CNTN3 FAM86D
FRG2C ZNF717 ROBO2 ROBO1
25q31.3q33.1 ,142.91–148.19. t-1, t-2, t-4, t-5 5.28 ADRB2 DPYSL3 HTR44 POU4F3 PPP2R2B
SPINK1 JAKMIP2 TCERG1 SPINK5 LARS
RBM27 KCTD16 HMHB1 FBXO38 YIPF5
SPINK7SCGB3A2 GPR151 PRELID2
SH3RF2 PLAC8L1 STK32A SPINK6 SPINK9
+6q27,168.12–168.32.[1.50] t-9, t-17 0.20 KIF25 FRMD1 HGC 6.1.1
27p22.2 ,3.02–3.12. t-5, t-6, t-7, t-9, t-10 0.10 GNA12 CARD11
+7p15.2 ,27,15–27,18. t-14, t-16, t-17, t-19 0,03 HOXA6 HOXA7 HOXA9 HOXA10 miR-
196b
27q21.3 ,97.69–101.88. t-2, t-5, t-6, t-7, t-9, 4.19 NPTX2 LMTK2 BRI3 BAIAP2L1 BHLHB8
CUX1
t-10 miR-86 miR-93miR-106b miR-548o
27q33q34,135.74–137.48. t-2, t-5, t-6, t-7, t-8, t-9 1.74 CHMR2 PTN DGK1 CREB3L2 miR-490
+8q24.3 ,143.73–143.9. t-3, t-14 0.17 PSCA LY6D JRK C8orf55 LY6K
SLURP1 LYNX1 LYPD2
212p13.2p13.1,11.82–13.33. t-2, t-4, t-5 1.51 ETV6 CDKN1B CREBL2 EMP1 GPR19 LRP6
GPRC5A HEBP1DDX47 MANSC1 GPRC5D
KIAA1467 BCL2L14 DUSP16 APOLD1
GSG1
HTR7P miR-613 miR-614 miR1244
+17q21.3 ,22.80–78.65. t-15, t-24 55.85 Whole 17q
221q22.1 ,35.11–35.15. t-7, t-8, t-11, t-29 0.04 RUNX1
p-AML
+1q21q22,153.19–154.64. p-23, p-24 1.4 .25 genes EFNA4 R1AP1 DPM3
YY1AP1 DAP3 ROBLD3 CCT3 CLK2
+1q32.1q44,201.31–247.19. p-6, p-23 45.69 Numerous genes
23p21.3,44.20–49.02. p-21, p-24, p-32 5.18 .40 genes SMARCC1 NCKIPSD
27q31.2q36.3,115.49–158.78. p-1 and p-2, p-7 43.29 Numerous genes
29q22.3q31.1,93.92–103.96. p-18, p-21 9.81 .60genes FANCC XPA
Amp 21q21.1,14.29–17.97. [5.46] p-4, p-21 3.78 LIPI ABCC13 RBM11 HSPA13 SAMSN1
NRIP1 USP25 C21orf34 CXADR BTG3
miR-99a miR-125b-2hsa-let-7c
Amp 21q22.2,38.27–43.54. [3 & 5.2] p-4, p-21, p-24 5,25 DSCR4 KCNJ15 ERG ETS2 BRWD1
other genes
+21q22.3qter,43.54–46.91. p-4, p-21, p-24 7.49 .50 genes
Column 1, the location of the MCR that follows the rules of tables 4 and 5; the figures in brackets and in bold are the ratios of the amplified regions. Column 2, patients;
the figures in bold indicate the smaller CNA.
doi:10.1371/journal.pone.0016623.t006
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translocation on an unidentified chromosome in addition to the
classic t(8;21) derivatives. In case p-18, a p-AML with a t(8;21),
a 1Mb loss on 8q21.3 amputated the first 59 exons of
RUNX1T1, probably inactivating the ETO-AML1 chimeric
gene on the der(21) and left the 39 RUNX1T1 coding sequence
intact in the AML1-ETO transcript on the der(8) [22]. This
cryptic rearrangement allowed a ‘‘virtual cloning’’ of the
t(8;21). The detailed molecular mechanisms of these rear-
rangements with an apparently identical t(8;21) seems to be
different in these secondary and de novo leukemias.
MCR
In the present series, twelve MCRs were isolated in t-AML
and 8 in p-AML (table 6). The size of MCRs was smaller in t-
AML, with a minimum of 0.04Mb compared to 1.4 Mb in p-
AML. There were 7 MCR of ,2Mb in p-AML compared to
only 1 in p-AML. The longest MCR in t-AML was 55 Mb, of
t h es a m eo r d e ro fm a g n i t u d ea si np - A M Lw h e r ei tw a s
45.69 Mb. A quarter of MCR contained sites for microRNAs
(miRNAs). They have been shown to be involved in different
biological processes, and in particular, hematopoiesis [23,24].
They are also described as behaving as tumor suppressor genes
or oncogenes [25,26]. Few new studies have reported on
molecular abnormalities implicating miRNAs that can be up- or
down-regulated in AML [27].
Table 8 and table 9 present the MCR from the data reported in
the literature [18,19,20,28,29,30,31,32,33,34]. Despite a certain
amount of heterogeneity in the samples, the techniques, the
genome constructs and other parameters, this table provides a
global view of nearly 550 p-AML and 50 t-AML. It allowed us to
clearly show the MCR and their frequencies.
When we compared the number of losses and gain in the
‘‘table’’ sample to those in the present series, a chi2 test showed
that as they were not different, we could include them in the table.
In all AML 123 MCR were losses and 51 were gains. In t-AML,
34 MCR were losses and 4 were gains while in p-AML 34 were
losses and were 4 gains.
We will examine the lost and gained MCR found in our series
together with the most specific or frequent MCR found in this
table.
21q
A small juxta-telomeric MCR loss in-1q44 wasnot reported in p-
AMLand does notseem tobe very frequent (tables8 and 9).Among
more than twentygenes,SMYD3 is a histone methyltransferase that
plays a role in transcriptional regulation as a member of an RNA
polymerase complex. It is expressed in CD34 cells.
Table 7. Single CNA of interest.
Patients MCR unic cases Size (Mb) Possible genes
t-AML
t-2 +14q22.1 ,47.25–52.51. 5.26 .30 genes
t-2 218q11.2q12.1,21.74–24.41.[0.23] 2.67 SS18 (Synovialosarcoma translocation) +7
other genes
t-2 218q22.3q23,71.06–71.76. 0.69 TSHZ1 Colon cancer ag a zinc finger
protein
t-13 21q42.3.q44,233.13–247.19. 14.06 .100 genes
t-13 210q11.2,45.53–47.97. 2.44 .20 genes
t-5 212p13.2p13.1,11.82–13.33. 1.51 .20 genes ETV6 CDKN1B miR613 miR614
miR1244
t-22 +2p25.3 ,2.54–3.57. 1.03 TSSC1 TTC15 ADI1 RNASEH1
t-14 217q11.2 ,25.96–27.38. 1.42 EVI2A EVI2B NF1 OMG SH3GLP2 SUZ12
CRLF3 C17orf79
CENTA2 UTP6 C17orf42 ATAD5 RNF135
RAB11FIP4
LRRC37B SUZ12P miR193a miR365-2
t-15 24q31.2 ,146.62–146.67. 0.05 SMAD1
t-30 22p23.3,25.31–25.60. 0,10 DNMT3A miR1301
p-AML
p-24 +3p21.3,50.26–50.29.[2.54] 0.03 GNAI2 SEMA3B
p-24 +3p21.3,52.29–52.31.[4.00] 0.03 NCLYTK miR135a-1
p-21 +3p14.1,64.32–67.67.[4.59] 1.94 LR1G1
p-18 28q21.3q22.1,93.15–94.17.[0.63] 1.02 RUNXT1
p-22 212p12.1p13.2,11.40–21.20.[0.55] 9.8 ETV6 CDKN1B among more than 20 genes
p-24 217p11.2q12,0.18–29.54.[0.65] 29,36 multiple genes
p-24 +15q23,67.44–68.37.[3.64] 3.31 KIF23 RPLP1 TLE3 miR-629
p-22 218q21.2,48.99–51.05.[0.55] 2.06 DCC and 4 other genes
Column 2: The CNA were either lost or gained as indicated by a ‘‘2’’ or a ‘‘+’’; the locations on chromosomes are described following the ISCN 2009 with slight
modifications: sequence numbers are included between ,. and expressed in Mb, with a resolution of 10kb; linear ratios are written between brackets after an ‘‘6’’;
chromosomes with a linear ratio .2 (low level of amplification) or losses ,0.25 are labeled in bold and italics.
doi:10.1371/journal.pone.0016623.t007
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1p36.2 6 6 (1) 7.81–7.89 A, D, E PER3 UTS2
1p35.1 6 6 (1) 22.39–22.44 A, D, E
1p34.2 3 3 (0.5) 42.07–42.45 A, D, E KRC HIVEP3
1p31.3p31.1 3 2 (0.3) 1 (2) 67.07–69.95 A, D, E WDR78 MIERS1 C1orf141 IL12RB2 SERBP1
GADD45A GNG12 DIRAS3 GPR177 RPE65 DEPDC1
1q42.1 3 3 (0.5) 222.6–222.9 D CNIH4 WDR26 CR625980 CNIH3
1q44 2 2 (4) 241.94–247.19 K WDR64 EXO1 MAP1LC3C PLD5?CEP170 AKT3
ZNF238 C1orf101 FAM36A EFCAB2 KIF26B
SMYD3 TFB2M ADSS HNRNPU PPPDE1 AHCTF1
2p23.3 3 3 (0.5) 25.25–25.46 D, E
2p23.1 3 3 (0.5) 30.29–30.95 A, D, E
2q36.2 8 8 (1.4) 222.01–225.42 A, D, E EPHA4 PAX3 FARSB MOGAT1 ACSL3 KCNE4 AP1S3
WDFY1 SERPINE2 MRPL44 FAM124B CUL3 SCG2
3p26.3-p25.3 4 3 (0.5) 1 (2) 0–9.14 D, G
3p26.3 4 3 (0.5) 1 (2) 14.96–16.15 A, D
3p21.3 8 5 (0.9) 3 (6) 44.46–49.64 A, D, K Numerous ZNF more than 30 genes
3p14.1p12.3 3 3 (6) 69.67–79.19 A, K MITF FOXP1 EIF4E3 GRP27 PROK2 RYBP SHQ1
PPP4R2 PDZRN3 CNTN3 FAM86D FRG2C ZNF717
ROBO2 ROBO1
3q11.2q13.3 5 5 (0.9) 95.03–120.21 D, E more than 30 genes
3q13.1q13.3 2 1 (0.2) 1 (2) 106.75–109.60 D
3q13.3 3 2 (0.3) 1 (2) 117.78–118.40 D
3q24q29 3 2 (0.3) 1 (2) 160.62–162.14 D
3q24q29 3 2 (0.2) 1 (2) 164.51–165.39 D SI SLITRK3 CR612557
4q24 7 7 (1.2) 106.1–106.72 A, D TET2 PPA2 FLJ20184 INTS12 GSTCD
4q27q28 6 5 (0.9) 1 (2) 122.92–124.45 D ADAD1 IL21 BBS12 FGF2 NUDT6 SPATA5 SPRY1
4q31.2 4 4 (8) 146.62–146.67 D, K SMAD1
5q11.1 3 2 (0.3) 1 (2) 50.16–50.21 D
5q11.2 3 3 (0.5) 51.79–53.66 D
5q11.2 5 4 (0.7) 1 (2) 55.73–56.92 A, D
5q11.2 4 3 (0.5) 1 (2) 57.49–57.79 A, D
5q12.1 7 5 (0.9) 2 (4) 59.54–59.87 A, D, E
5q13 14 10 (1.9) 4 (8) 82.72–84.65 A, D, E, J VCAN HAPLN1 EDIL3
5q14.3q15 20 17 (3) 3 (6) 86.54–95.19 A, D, E, J CCNH TMEM161B MEF2C CETN3 POLR3G
RASA1 LYSMD3 GPR98 VLGR1 ARRDC3 NR2F1
FAM172A POU5F2 ANKRD32 MCTP1 UNQ630
TTC37 ARSK GPR150 RFESD RHOBTB3 GLRX
5q15q22.3 20 16 (2.6) 4 (8) 95.51–114.14 A, D, E, J PCSK1 CAST ERAP1 ERAP2 LNPEP LIX1 2
RIOK CHD1 PAM HISPPD1 NUDT12
CR610784 RAB9P1 EFNA5 FBXL17 FER PJA2
MAN2A1 TMEM232 TSLP WDR36 CAMK4
STARD4 C5orf13 EPB41L4A APC SRP19
ZRSR2 REEP5 DCP2 MCC YTHDC2 KCNN2
5q22.3q31.1 16 13 (2.3) 3 (6) 129.23–131.96 A, D, E, J CHSY3 LYRM7 CDC42SE2 RAPGEF6 FNIP1 ACSL6
CSF2 IL3 P4HA2 PDLIM4 IRF1 RAD50
5q31.1 21 12 (2.1) 9 (18) 133.52–134.26 A, D, E, H PPP2CA CDKL3 UBE2B PHF15 SAR1B CAMLG
DDX46 C5orf24 TXNDC15 PCBD2
5q31.3q33.1 19 11 (2) 8 (16) 142.91–148.19 A, D, E, J, K HMHB1 YIPF5 PRELID2 GRXCR2 RBM27 POU4F3 LARS
GPR151 PPP2R2B TCERG1 STK32A JAKMIP2
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SPINK1 SPINK5 SPINK6 SPINK7 SPINK9 FBXO38
HTR4 SH3TC2
5q33.3 14 10 (1.8) 4 (8) 156.39–156.51 A, D, E, J
5q33.3 13 10 (1.8) 3 (6) 157.25–158.80 A, D, E, J CLINT1 EBF1 RNF145 UBLCP1 IL12B
6p25.1p24.3 10 7 (1.2) 3 (6) 5.54–8.38 A, B, C, D FARS2 NRN1 F13A1 LY86 MMD-1 Zep-1
RREB1 SSR1 CAGE1 RIOK1 DSP BMP6
TXNDC5 MUTEDEEF1E1
6p22.3p22.2 5 4 (0.7) 1 (2) 20.29–23.74 A, B, D
6p22.2p22.1 6 5 (0.9) 1 (2) 24.15–26.16 A, B, D DCDC2 KAAG1 MRS2 GPLD1 ALDH5A1 TTRAP
ACOT13 GMNN FAM65B DKFZp686H12134
HIST1H cluster TRIM38 HFE
6q24.1 2 1 (0.2) 1 (2) 140.6–142.5 D, F
6q25.3 2 1 (0.2) 1 (2) 156.39–156.61 D
7p22.2 7 1 (0.2) 6 (12) 3.02–3.12 D, K CARD11
7p14.1 4 3 (0.5) 1 (2) 39.5–41.7 D, F
7p12.2 2 2 (0.3) 50.18–50.45 D IKZF1
7q21.1 4 3 (0.5) 1 (2) 85.41–86.44 A, C, E
7q21.1 5 5 (10) 90.21–90.44 A, D PFTK1
7q21.3q22.1 14 6 (1) 8 (16) 97.69–100.36 A, D, E, K LMTK2 BHLHA15 TECPR1 BRI3 NPTX2
TMEM130 TRRAP SMURF1 KPNA7 MYH16
ARPC1A PDAP1 BUD31 PTCD1 CPSF4 ATP5J2
ZKSCAN5 CYP3A4 TRIM4 COPS6 MCM7
TAF6 GATS PILRB PILRA ZCWPW1 MEPCE
FBXO24 GNB2 EPO mir-25 mir-93 mir-106b
7q31.3 16 15 (2.7) 1 (2) 121.7–123.9 B, D, F, J, K PTPRZ1 LKR/SDH AASS FEZF1 CADPS2 RNF133
TAS2R16 NDUFA5 ASB15 WASL HYAL4
7q33q34 22 15 (2.7) 7 (14) 135.74–137.48 B, D, E, J, K CALD1 TMEM140 STRA8 WDR91
CNOT4 NUP205 FAM180A TPN miR490
7q34 20 19 (3.4) 1 (2) 139.72–140.02 B, D, E, J, K TBXAS1 PARP12 MST109 JHDM1D KIAA1718
7q35q36.1 16 16 (2.9) 146.12–148.2 B, D, E, J, K CNTNAP2
7q36.1q36.2 16 15 (2.7) 1 (2) 152.02–152.80 A, B, D, E, J, MLL3 XRCC2 ACTR3B FABP5L3
K
8p23.2 3 2 (0.3) 1 (2) 3.48–3.58 A, D
8p22p21.3 2 1 (0.2) 1 (2) 18.72–21.93 D
8p21.2p12 2 1 (0.2) 1 (2) 24.40–36.30 D
8q22.1 3 3 (0.5) 93.15–94.17 A, K C8orf83
8q24.1 4 3 (0.5) 1 (2) 117.81–118.38 I
8q24.1q24.2 4 3 (0.5) 1 (2) 126.54–129.58 A, D
8q24.2 3 3 (0.5) 130.53–130.80 A, D
8q24.2q24.3 3 2 (0.3) 1 (2) 131.51–146.26 A, D
9p24.3p13.3 4 4 (0.7) 0.19–33.18 A, D, E
9q21.3 5 4 (0.7) 1 (2) 82.37–84.44 B, C, D, E
9q22.3q31.1 5 5 (0.9) 93.92–103.96 C, D, E, K more than 30 genes
9q32q33.1 2 2 (0.3) 116.51–117.92 B, D
10q23.1q23.3 4 4 (0.7) 87.93–90.77 C, D
10q24.1q24.2 4 4 (0.7) 96.48–100.81 C, D
11p15.5p15.4 8 7 (1.2) 1 (2) 2.48–3.35 B, C, D, E KCNQ1 KCNQ1OT1 KCNQ1DN CDKN1C
SLC22A18NAP1L4 PHLDA2 CARS
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OSBPL5 C11orf36 MRGPRE
11q12.3q13.1 3 3 (0.5) 63.98–65.65 D
11q13.1q25 4 4 (0.7) 67.25–134.24 B, D, E
11q23.3 4 2 (0.3) 2 (4) 117.86–119.81 A, D, E
12p13.3 4 2 (0.3) 2 (4) 0.06–4.05 D, E
12p13.2 10 6 (1) 4 (8) 10.62–11.72 C, D, E, J
12p13.2 12 10 (1.8) 2 (4) 11.2–12.70 C, D, E, F, J
12p13.2p13.1 17 14 (2.5) 3 (6) 12.20–13.13 C, D, E, J, K ETV6 BCL2L14 LRP6 MANSC1 LOH12CR1
AX748225 DUSP16 CREBL2 GPR19 CDKN1B
APOLD1 DDX47 GPRC5A TVAS4 HEBP1
12p12.3 7 5 (0.9) 2 (4) 15.54–19.17 C, D, E, J, K PTPRO EPS8 STRAP MGST1 LMO3 RERGL PIK3C2G
CAPZA3
12q12 3 2 (0.3) 1 (2) 42.64–43.26 A, D
12q13.1 2 2 (0.3) 46.06–46.30 A, D
12q24.3 4 3 (0.5) 1 (2) 81.57–105.06 A, D, E
12q24.3 3 2 (0.3) 1 (2) 121.28–122.73 A, D
12q24.3 3 3 (0.5) 128.71–128.91 A, D, E
13q14.3 8 7 (1.2) 1 (2) 49.63–50.51 C, D, E
13q21.1 4 4 (0.7) 54.33–54.45 B, D
16p11.1q12.1 20 20 (3.6) 35.06–50.12 D, G VPS35 SHCBP1 ORC6L MYLK3 GPT2 DNAJA2
NETO2 ITFG1 PHKB ABCC12 ABCC11 LONP2 SIAH1
LONP N4BP1 CBLN1 HEATR3
16q21 24 23 (4.1) 1 (2) 57.56–58.96 B, D, G GPR114 GPR56 GPR97 CCDC135 KIFC3 CNGB1
TEPP MMP15 CSNK2A2 GINS3 NDRG4 SETD6
CNOT1 GOT2
16q21 26 24 (4.3) 2 (4) 62.51–63.81 D, G, J
16q22.3 25 22 (4) 3 (6) 70.76–71.46 D, G, J VAC14 HYDIN FTSJD1 CALB2
16q22.3q23.1 26 26 (4.7) 73.30–73.57 G, H, J BC042734
16q24.1 24 23 (4.1) 1 (2) 83.37–85.07 D, G, J CDH13 HSBP1 MLYCD OSGIN1 NECAB2 MBTPS1
HSDL1 LRRC50 TAF1C ADAD2 KCNG4 USP10
16q24.3 26 26 (4.7) 87.30–87.37 G, J, K FBXO31
17p13.2p13.1 22 16 (2.9) 6 (12) 4.01–8.20 A, D, J TP53 NLRP1 NUP88 C1QBP XAF1 and more than
30 genes
17p12p11.2 7 5 (0.9) 2 (4) 14.74–19.35 A, D, E
17p11.2 4 3 (0.5) 1 (2) 20.02–21.45 C, D, E
17q11.2 44 39 (7.1) 5 (10) 26.49–27.52 A, D, E, G, NF1 EVI2A EVI2A
H, J, K
17q21.33 4 2 (0.3) 2 (4) 44.98–45.43 D, E
17q21.33 3 3 (0.5) 46.22–47.56 D, E
17q25.1q25.3 2 2 (0.3) 69.43–73.16 D
18p11.32p11.31 14 12 (2.1) 2 (4) 1–4.62 D, G, J C18orf2 METTL4 NDC80 SMCHD1 EMILIN2
LPIN2 MYOM1 MYL12B TGIF1 DLGAP1
18p11.23 17 16 (2.9) 1 (2) 7.42–7.58 G, H, J PTPRM
18p11.22p11.21 5 4 (0.7) 1 (2) 9.03–13.81 D, H
18q11.2 9 8 (1.4) 1 (2) 18.1–22.05 D, G
18q11.2q12.2 21 18 (3.2) 3 (6) 21.74–33.13 D, G, K CABYR OSBPL1A IMPACT HRH4 ZNF521 SS18
PSMA8 TAF4B CDH2 DSC3 DSC1 DSC2 DSG4
DSG3 DSG2 TTR RNF125 DTNA MAPRE2
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Two MCR were found. The most telomeric one on 3p21.3 was a
5.18 Mb recurrent loss covering more than 40 genes. It was found
in p-AML (table 6, figure 1) but also in t-AML (tables 8 and 9).
A more centromeric 10Mb loss was found exclusively in t-AML.
Both patients in the present work contributing to this MCR had
been treated with RT and 5FU. PROK2, a prokineticin 2 isoform
A precursor, is highly expressed in bone marrow [35] and could
have chemokine-like activity [36]. Another gene, the SHQ1
homolog, expressed in CD34 cells has been purported to be
required for the assembly of H/ACA small nucleolar and
telomerase RNPs [35,37].
24q
A specific loss in p-AML was found in 4q24 (table 8) including
TET2, a tumor suppressor gene described in myeloid cancers [38].
A small loss of 4q31.2, exclusively in 8% of t-AML (tables 7 and
8) was found to delete the 59 half of SMAD1. This protein
mediates the signals of bone morphogenetic proteins (BMPs),
which are involved in a range of biological activities including cell
growth, apoptosis, morphogenesis, development and immune
responses. It is expressed in BM cells (UCSC).
25q
The 5q- region was fragmented in more than twelve groups. In
p-AML, the most frequent regions were comprised between 86.54
and 114.14 Mb, with proximal and distal ‘‘spreading’’. This
region contains the RASA1 gene which exhibits tumor suppressor
activity on the RAS gene. RASA1 has been reported to be a CNA
in breast cancers and a putative tumor suppressor gene [39].
PCSK1 may be implicated in malignancy [40]. APC and MCC
genes are implicated in colorectal cancer. The more proximal area
contains the AML/MDS region that Evers considered as a 5.2 Mb
MCR [41].
Two MCR were observed in more than 10% of t-AML (table 8).
Both were proximal to the previously reported 7.7 Mb 5q33.3
region [41]. The first MCR was located on 5q31 and was smaller
than 1Mb. It contained several genes of interest such as CDKL3,
an important regulator of cell cycle progression, UBE2B that is
required for post-replicative DNA damage repair, and the helicase
DDX46 which is highly transcribed in bone marrow.
The second 5.22 Mb MCR in 5q31.3q32, was delineated by the
present work (table 6). Among the 29 genes it harbored, several are
overexpressed in bone [35]. PRELID2 codes for a protein
containing a PRELI/MSF domain. It is an evolutionary conserved
gene [42,43]. TCERG1 is a transcription factor that binds RNA
polymerase II, inhibits the elongation of transcripts from target
promoters and regulates transcription elongation in a TATA box-
dependent manner. LARS encodes a cytosolic leucine-tRNA
synthetase, a member of the class I aminoacyl-tRNA synthetase
family. FBXO38 is a F-box protein 38 isoform A that is
overexpressed in early erythroid cells. FBXO32, a family member
of these cells, is a PRC2-targeted gene [44]. POU4F3, a POU class
4 homeobox 3 is a member of the POU-domain family of
transcription factors that is not expressed in bone marrow but in
monocytes. Furthermore, another member of the POU gene
family, POU4F1, has been recently described to be associated with
AML exhibiting t(8;21) [45]. RBM27 is a zinc finger RNA-binding
protein member of the family that includes RBM15, alias OTT,
which is involved in the regulation of hematopoietic stem cells and
is fused with MKL1 in the t(1;22) of AML7 and plays a major role
in the pathogenesis of this disease [46].
Finding different MCR with a maximum frequency in p-AML
and in t-AML suggests different oncogenesis pathways on this
chromosome.
7p MCR
A 90kb MCR in 7p22.2 (table 6 and 8) had deleted he CARD
11 gene in t-AML. The CARD domains of this caspase have been
shown to activate NF-kappaB and to induce the phosphorylation
of BCL10 when expressed in CD34+ cells [47]. CARD 11, via the
immune cell restricted complex CARD11-BCL10-MALT1, [48] is
implicated in lymphoma.
In three t-AML cases, a gain of 7p15 concerned the homeogene
cluster of HOXA6, HOXA7, HOXA9 and HOXA10 (Table 6).
This area has not been described as a CNV [7]. The HOXA
Chromosome All p (%) t (%) consensus MCR References Genes
abnormalities location in Mb
18q21.1 21 20 (3.6) 1 (2) 43.39–46.37 D, E, G, K HAUS1 LOXHD1 PIAS2 SMAD2
18q21.2 22 20 (3.6) 2 (4) 50.21–51.05 D, E, G, K RAB27B CCDC68
18q21.32 22 20 (3.6) 2 (4) 55.08–55.51 D, E, G, J, K ONECUT2 FECH NARS ATP8B1
18q22.3 23 22 (4.0) 1 (2) 69.06–69.18 D, E, G, K
18q22.3q23 4 2 (0.3) 2 (4) 71.06–71.76 E, G, J FBXO15
19p13.3 3 2 (0.3) 1 (2) 0.21–1.81 A, D
19q13.2q13.43 2 2 (0.3) 46.16–63.43 C, D
20q11.2q13.1 2 2 (0.3) 34.59–43.45 E more than 30 genes
20q13.1q13.3 2 2 (0.3) 43.85–55.73 E more than 30 genes
21q22.12 11 7 (1.2) 4 (8) 35.11–35.15 A, D, K RUNX1
21q22.3 3 3 (0.5) 44.70–45.09 D
The first column lists the chromosomal losses and gains. The second lists the absolute number of each rearrangement (excluding a single rearrangement). The third and
the fourth are the absolute numbers in p-AML and t-AML respectively and the percentage is indicated between parenthesis. The chromosomal location is listed. The
references are indicated by letters: A [32], B [33], C [34], D [18], E [19], F [28], G [29], H [30], I [31], J [20], K present work. The last column lists the genes included in those
MCR.
doi:10.1371/journal.pone.0016623.t008
Table 8. Cont.
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Chromosome All p (%) t (%) consensus MCR References Genes
abnormalities location in Mb
GAINS
1q21.3q22 4 3 (0.5) 1 (2) 153.19–154.64 C, D, K S100A8 S100A9 S100A13 S100A6 SNAPIN ILF2
NPR1 INTS3 VLCS-3 GATAD2B TORC2 CREB3L4
TPM3 HAX1 IL6R SHE UBE2Q1 ADAR CHRNB2
1q32.1 3 2 (0.3) 1 (2) 204.98–205.04 C, D
1q32.1q44 6 5 (0.9) 1 (2.1) 235.00–235.10 A, B, K BC016972 ?
3q26.3q29 2 2 (0.3) 182.99–133.31 E more than 30 genes
4p13q12 2 2 (0.3) 42.30–58.23 B, D
4q12q13.1 2 2 (0.3) 59.13–62.98 B, D
4q28.3 2 2 (0.3) 132.8–136.7 B, G
5p13.2q11.1 2 1 (0.2) 1 (2) 37.98–50.15 A, D
5q11.2 3 2 (0.3) 1 (2) 51.21–54.12 A, D
6q11.2q12 8 8 (1.4) 63.43–63.7 A, G
6q27 3 2 (0.3) 1 (2) 168.12–168.32 D, K MLLT4 avoir table 6
7p15.2 4 4 (8) 27.15–27.18 K HOX genes
8q24.3 16 12 (2.1) 4 (8) 143.73–143.90 B, D, G, I, J, K JRK PSCA LY6K C8orf55 LYPD2 SLURP1 LYNX1
LY6D
9p21.3 2 2 (0.3) 21.5–23.4 F, G
9q13q21.3 2 2 (0.3) 70.23–83.52 E FXN APBA1 TJP2 SMC5 TRPM3 GDA TCM1
ANXA1
RARB RFK GNA14 TLE4 TLE1
11q12.1q14.1 16 16 (2.9) 59.1–79.6 G more than 50 genes
11q14.1 5 5 (0.9) 79.6–81.3 D, G
11q24.2q24.3 31 31 (5.6) 126.53–130.23 D, E, G, J KIRREL3 ETS1 FLI1 C11orf45 TP53AIP1 RICS
BARX2 NFRKB PRDM10 APLP2 ST14 ZBTB44
12p13.33p11.21 13 13 (2.3) 0.1–32.7 E, G no gene
13q12.11q13.1 3 3 (0.5) 19.9–31.7 G
13q31.3 2 2 (0.3) 90.45–90.97 E GPC5
15q21.1 3 3 (0.5) 46.52–47.36 B, D, E
15q21.3q22.1 3 3 (0.5) 55.6–56.6 B, E, F
15q23 5 5 (0.9) 67.44–68.37 B, E, J SMAD3 AAGAB MAP2K5 LBXCOR1 PIAS1
15q26.q26.3 6 6 (1) 92.5–100.0 C, E, G
17q12 6 4 (0.7) 2 (4) 32.82–33.20 C, D, E, J TMEM132E
17q21.2q21.31 5 3 (0.5) 2 (4) 37.08–38.48 D, E, J FBXO47 PLXDC1 FBXL20 MED1 CRKRS TCAP
PGAP3 ERBB2 GRB7 IKZF3 GSDMB ORMDL3
PSMD3 CSF3 MED24 THRAP4 NR1D1 MSL1
CASC3
WIPF2 CDC6 RARA
19p13.3p13.12 13 13 (2.3) 2.19–14.11 D, G, J
19p13.12p13.11 13 13 (2.3) 16.0–16.15 F, G, J
19q13.31 2 2 (0.3) 49.2–49.9 D, F
19q13.41 2 2 (0.3) 58.3–59.1 D, G
20q11.1q11.21 3 3 (0.5) 28.2–30.5 E, G
21q21.1 2 2 (0.3) 14.29–17.97 K LIPI ABCC13 RBM11 HSPA13 SAMSN1 NRIP1
USP25 C21orf34 CXADR BTG3
miR-99a miR-125b-2 hsa-let-7c
21q22.2 18 18 (3.2) 38.65–38.85 C, D, G, J, K ERG ETS2
21q22.3q 4 4 (0.7) 45.09–46.91 D, K RRP1B PDXK RRP1 CSTB AGPAT3 TRAPPC10
t-AML and p-AML aCGH
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play an important role in the development of body segmentation
and in the survival of hematopoietic stem cells. HOXA6 is directly
implicated in the process of hematopoietic progenitor cell
development. HOXA9, that can be fused with NUP98 in some
AML [49], is fundamentally involved in the AML process in
transgenic mice [50,51,52].
These genes belong to the HOXA5-11 cluster and are expressed
throughout the CD34+ compartment [53,54]. The CD34+ level
becomes important in AML due to the immature status of blastic cells.
As overexpression of Abd-B HOXA genes has been demonstrat-
ed in AML with a rearranged MLL [55], the gain of the HOXA
cluster could be expected in case t-19 which had a t(9;11). The other
t(v;MLL) did not exhibit this gain. The other two patients with such
a gain (cases t-17 and t-14) had a t(15;17) and a +8 respectively.
They were cytologically and cytogenetically different and had wild
type MLL. The HOX gain was not detected in p-AML.
27q
On 7q, the 11 MCR with a specificity for t-AML or p-AML were
interlaced. Three MCR were reported in more than 10% of t-AML
(table 8). The first one is 7q21.1 with a small region potentially
implicating PFTK1,a memberof a proteinkinase family whose gain
was recently shown to be involved in hepatocellular carcinoma cells.
The most frequent MCR in t-AML was 7q21.3q22.1 (tables 6
and 8). The number of genes present in this almost 3 Mb-long
MCR prohibited extensive reviewing.
Three miRNA, mir-25, mir-93 and mir-106b were present in this
deleted region (table 6 and table 8), regulatingnumerous genes. The
miR-106b,25 cluster cooperates with its host gene MCM7 in
cellular transformation both in vitro and in vivo, so that the
concomitant overexpression of MCM7 and the miRNA cluster
triggers prostatic intraepithelial neoplasia in transgenic mice [56].
MCM7canbe associated with CDK4that mayregulatethebinding
of this protein to the tumor suppressor protein RB1/RB. Among 30
genes, BRI3 appears to be overexpressed in BM-CD33+ cells. It
seems to play a key role in TNF-induced cell death [57].
A defect in DNA repair was reported in TRRAP-deficient cells
[58].
In 7q33q34, a 1.74Mb MCR had a low ratio in a patient (t-2),
implying a probable double deletion, while the remaining ratio
could have been due to the few normal cells. This MCR was the
third in t-AML. It contained miRNA-490 which was probably
regulating fewer than a hundred genes, with a maximum context
score for the FOS gene. Among several genes (table 6), CREB3L2
was overexpressed in BM-CD34+ cells. It is a DNA binding and
basic leucine zipper dimerization (bZIP) transcription factor. It
was reportedly fused with FUS in fibrosarcomas [59] via a
t(7;16)(q34;p11) and with PPAR gamma in a subset of thyroid
carcinoma via a t(3;7)(p25;q34) [60].
In our series of p-AML, a large 43 Mb MCR was situated
between 7q31.3 and the telomere (table 6). Table 8 allowed us to
divide this region into 5 smaller MCR that seemed to be different
from those of t-AML. The only exception was the previously
identified 7q33q34 MCR that was the only MCR common to t-
AML and p-AML in the loss of 7q.
The most centromeric p-AML-specific deletion was a 2.2Mb
MCR on 7q31.3. Among the 10 genes in the region, only WASL is
reported to potentially play a role in the microthrombocytopenia,
the characteristic sign of Wiskott-Aldrich syndrome [61].
The 7q34 MCR was the most frequent and the most specific in
p-AML. It contains 5 genes (table 8) that are not obviously
involved in malignancy and some (e.g. PARP12) are poorly known
but all are more or less strongly expressed in CD33 myeloid cells.
They were located between 7q31.3 and 7q36.2. Obviously,
there are too many genes in those 5 MCRs, but PTPRZ1, MLL3
and XRCC2 could be candidate leukemogenic genes.
+8q24.3
A gain of 170 Kb located on 8q24.3 was selected as a MCR
from two cases in the present group of t-AML (Figure 1). This
MCR was confirmed in other series (table 9), frequently in t-AML
(8%) and less frequently in p-AML (2.1%). This finding is
consistent with the +8q22qter MCR being the ‘‘drive’’ genes of
trisomy 8 which can be observed in some t(8;21) AML [62]. This
MCR was telomeric to the MYC and TRIB1 genes [63]. PSCA,
implicated in prostate cancer and C8orf55, the ‘‘mesenchymal
stem cell protein DSCD75’’ which plays a role in bone marrow
cell interactions, could not be excluded. However JRK, which is
moderately overexpressed in BM-CD34+ cells [6] encodes a
putative DNA-binding protein [64] and exhibits homology with
the CENP-B (centromere-binding protein B).
Chromosome All p (%) t (%) consensus MCR References Genes
abnormalities location in Mb
GAINS
TMEM1 PWP2 C21orf33 ICOSLG DNMT3L AIRE
PFKL TRPM2 LRRC3 UBE2G2 SUMO3 PTTG1IP
PBF
ITGB2 ADARB1 COL18A1
22q12.3 13 12 (2.1) 1 (2) 33.90–35.32 D, G LARGE
22q13.1q13.2 14 13 (2.3) 1 (2) 36.78–42.24 D, G more than 30 genes
22q13.31q13.32 11 10 (1.8) 1 (2) 44.92–48.08 D, G PRR5 ARHGAP8 PHF21B NUP50 UPK3A SMC1B
ATXN10 WNT7B GTSE1 GRAMD4
The first column lists the chromosomal losses and gains. The second lists the absolute number of each rearrangement (excluding a single rearrangement). The third and
the fourth are the absolute numbers in p-AML and t-AML respectively and the percentage is indicated between parenthesis. The chromosomal location is listed. The
references are indicated by letters: A [32], B [33], C [34], D [18], E [19], F [28], G [29], H [30], I [31], J [20], K present work. The last column lists the genes included in those
MCR.
doi:10.1371/journal.pone.0016623.t009
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Although no such result was found in our study, 5.6% of the p-
AML in other series clearly showed gains or amplifications of this
region that contains ETS1 and FLI1 genes. They are members of
the ETS gene family that includes genes playing important roles in
regulating hematopoiesis, proliferation, differentiation and apop-
tosis. Interestingly, these gains were found in cases presenting gains
of the ETS2 and ERG genes (see below, the +21q22 paragraph).
212p13
A 1.48Mb loss was defined as a MCR from three t-AML cases
in the present report. The same area is recurrently lost in both
types of AML (table 7, table 8). Among 17 genes, the 59 part of
ETV6 was lost. This ETS family transcription factor is a multi-
partner gene with almost 28 different fusion genes via reciprocal
translocations. It is implicated in multiple myeloid malignancies
such as MDS and AML, but also in lymphoid malignancies and in
fibrosarcomas [49]. CDKN1B encodes a cyclin-dependent kinase
inhibitor. These two genes are considered as having tumor
suppressor activity.
217p13.2p13.1
Although no deletion of this region was found in our series,
several reports claimed a loss of this MCR in 12% of t-AML and
3% of p-AML. This region, among several genes, exhibits loss of
the TP53 tumor suppressor gene [49].
Figure 2. aCGH karyogram of patient t-8 and MCR delineation of RUNX1. A=A del (7q) and trisomy 13 are obvious. Cryptic deletions from
21q22.1 (corresponding to RUNX1) and from Xp11.4, that are smaller than 60kb, are nullosomic. On 22q11, the loss is a constitutive CNV of GGT1.
B=A UCSC map (build 18) of the RUNX1 gene. C=The deletions of RUNX in four patients at the molecular level are labeled in orange and the smallest
in red. The location of the breakpoints are indicated at the ends of the colored lines. Patient t-8 exhibits a homozygous 590 Kb deletion that
encompassed the entire RUNX1 gene and could have occurred by an acquired isodisomy. Patient t-11 had the smallest deletion (40Kb) that was
internal to RUNX1; t-29 had a deletion limited to RUNX1.
doi:10.1371/journal.pone.0016623.g002
t-AML and p-AML aCGH
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This MCR, that we found in a single case of t-AML (table 7), is
the most frequent loss of the table 8 with 7.1% of in p-AML and
10% of in t-AML. This MCR contains the NF1 tumour suppressor
gene NF1 which encodes neurofibromin, a GTPase-activating
protein that negatively regulates RAS signaling by stimulating
hydrolysis of Ras-GTP. Loss of NF1 can lead to a progressive
myeloproliferative disorder in animal models [65] and in Juvenile
myelomonocytic leukemia. Parkin [19] concluded that NF1 null
states were present in 7% of AML. This important point
confirmed that additional events were are required.
218
Loss of different parts of chromosome 18 were highly recurrent
in p-AML (table 8). In our series, we found a single p-AML with a
2.06 Mb deletion that had an equivalent MCR in table 8 which
contains RAB27B and CCDC68 genes.
221q22.12
This 40kb small MCR contains RUNX1 that was lost in 4 t-
AML cases in the present series. Two patients had lost their two
alleles either through double losses or deletion and D171N
mutation. This mutation has been claimed to result in the
proliferation of immature myeloid cells, an enhanced capacity
for self-renewal, and the proliferation of primitive progenitors
[66].
Patient t-29 had a normal karyotype [32] and a 310kb deletion
that deleted most of the gene in a radiotherapy-induced leukemia
[67].
Three deleted cases were exposed to multi-agent chemotherapy
with alkylating agents. They exhibited a 7q-/-7 as previously
reported [68] as well as patient t-12 that had a balanced
abnormality involving RUNX1, only detected by classical
karyotype. It has been suggested that the mutation of RUNX1
and gene losses localized on 7q could cooperate in leukemogenesis
and predispose to leukemic transformation into t-AML following
alkylating agents (figure 2). In table 8, seven other cases were
observed in p-AML.
RUNX1, the subunit alpha of the Core Binding Factor (CBF), a
heterodimeric transcription factor, plays a key role in the
regulation of hematopoietic stem cell proliferation and differen-
tiation. It is one of the most frequent targets of chromosome
translocations via nearly forty different partners [49] in various
forms of leukemia.
A germline mono-allelic mutation or deletion of RUNX1 [69]
has been described in FPD (Familial Platelet Dysfunction) disease.
A second mutation may appear at the AML stage, mostly with an
M0 type in the FAB classification [70].
Figure 3. p-AML (case p24) with a complex karyotype. See the amplification of 15q23q24 and of 21q11.2q22.1 that are enlarged at the gene
level. Multiple abnormalities (cf table 5) are asterisked.
doi:10.1371/journal.pone.0016623.g003
t-AML and p-AML aCGH
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induced MDS [67] or in therapy-induced transformation of
myeloproliferative neoplasia [66].
Haploinsufficiency of RUNX1 leads to the loss of function of
this gene (probably a tumor suppressor function). In the case of t-
AML, the various point mutations are localized at the N-terminal,
the DNA binding site [68].
+21q22
Distal 21q11.2qter polysomy was observed in three cases
(table 6), two of which exhibited amplifications of this region in
the context of a complex karyotype [21].
The first amplicon (table 5 and 6) from 14.29 to 17.97Mb
harbored a cluster of miR-99a, miR-125b-2 and hsa-let-7c, each of
which is predicted to regulate several hundred genes. Several of
the genes in this amplicon (table 6) were overexpressed [35] in
BM-CD34+ cells. SAMSN1, a hematopoietic adaptor was found
to contain the SH3 and SAM domains 1, HSP13, BTG3 and
NRIP1. This region was reported to be amplified by BAC aCGH
in a series of patients with complex karyotypes [71] which showed
that NRIP1 and SAMSN1 genes were up-regulated compared
with their status in patients with normal karyotypes. The same
area from LIP1 to miR-125b-2 is reported to be homozygously
deleted in the Non-Small Cell Lung Cancer cell line Calu-6 [72].
The 1Mb-long second amplicon, observed in cases p-21 and p-
24 was found to occur frequently in p-AML (table 9) and most of
the cases also exhibited a gain of ETS1. It contained ERG and
ETS2 genes. These two ETS transcription factor gene family
members were overexpressed in BM-CD34+ cells. ERG can be
fused with several genes in prostate cancer [73], in Ewing tumors
[74] and in leukemias with a t(16;21)(p11;q22) and an FUS-ERG
fusion [49]. It has been claimed that ERG is a megakaryocytic
oncogene [75] together with ETS2 [76].
ERG and ETS2 were amplified in p-AML with complex
karyotypes (figure 3) and ETS2 overexpression was highly
correlated with the amplification, unlike ERG [71,77]. The
preliminary results of a transcriptome study of case p-21 are in
agreement with these findings. The RUNX1 region was not
amplified in p-AML in our small sample.
Conclusion
High resolution cytogenomics obtained by aCGH and similar
techniques already published allowed us to characterize numerous
untargeted non random chromosome abnormalities. This work
supports the hypothesis that they can be classified into several
categories: abnormalities common to all AML (e.g. 8q24.3 gain or
17q11.2 deletion involving NF1); those more frequently found in t-
AML (e.g. 7q21 or 7q33 deletions or even the specific gain of
HOX genes); and those specifically found in p-AML (e.g. loss of
the 139 to 152.8 Mb of 7q, 11q24 gain or 21q22 with
amplifications of ERG and ETS2).
The genes involved in AML MCRs are often very well known in
leukemogenesis but many others need to be explored.
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